SK Hynix Shares Fall as Workers Reject Wage Deal 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Trump Buys SpaceX Shares After Record IPO 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
 - EconoTimes)
Add as a preferred source on Google
PRESS RELEASE
Active Biotech's Annual Report 2017 is now available för download at www.activebiotech.com.
The Annual Report will only be digitally distributed. The English version will be available within short.
Lund, April 23, 2018
Active Biotech AB (publ)
Helén Tuvesson
CEO
For further information, please contact:
Hans Kolam, CFO
Tel. +46 (0)46 192044
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties is in development for neurodegenerative diseases in partnership with Teva Pharmaceutical Industries Ltd. ANYARA, an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
This information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 11.30 am CET on April 23, 2018..
Attachment
